Asunto(s)
Docetaxel/efectos adversos , Uñas Encarnadas/diagnóstico , Uñas/efectos de los fármacos , Neoplasias de la Próstata/tratamiento farmacológico , Moduladores de Tubulina/efectos adversos , Anciano , Humanos , Masculino , Uñas/crecimiento & desarrollo , Uñas/cirugía , Uñas Encarnadas/inducido químicamente , Uñas Encarnadas/cirugía , Dedos del Pie , Resultado del TratamientoAsunto(s)
Antineoplásicos/efectos adversos , Receptores ErbB/antagonistas & inhibidores , Uñas Encarnadas/terapia , Plásticos , Inhibidores de Proteínas Quinasas/efectos adversos , Quinazolinas/efectos adversos , Férulas (Fijadores) , Femenino , Gefitinib , Humanos , Persona de Mediana Edad , Uñas Encarnadas/inducido químicamenteAsunto(s)
Antiinfecciosos Locales/uso terapéutico , Antineoplásicos/efectos adversos , Granuloma Piogénico/tratamiento farmacológico , Granuloma Piogénico/cirugía , Uñas Encarnadas/tratamiento farmacológico , Uñas Encarnadas/cirugía , Fenol/uso terapéutico , Quinazolinas/efectos adversos , Anciano , Antineoplásicos/administración & dosificación , Femenino , Gefitinib , Granuloma Piogénico/inducido químicamente , Granuloma Piogénico/patología , Granuloma Piogénico/terapia , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/secundario , Uñas Encarnadas/inducido químicamente , Uñas Encarnadas/patología , Uñas Encarnadas/terapia , Quinazolinas/administración & dosificación , Dedos del Pie , Resultado del TratamientoAsunto(s)
Antifúngicos/efectos adversos , Uñas Encarnadas/inducido químicamente , Onicomicosis/tratamiento farmacológico , Administración Oral , Antifúngicos/uso terapéutico , Quimioterapia Combinada , Fluconazol/efectos adversos , Fluconazol/uso terapéutico , Humanos , Itraconazol/efectos adversos , Itraconazol/uso terapéutico , Naftalenos/efectos adversos , Naftalenos/uso terapéutico , Onicomicosis/microbiología , Estudios Retrospectivos , Terbinafina , Resultado del TratamientoRESUMEN
OBJECTIVE: To report five cases of ingrown toenails (IGTN) associated with indinavir/ritonavir (IDV/RTV) combination therapy. CASE SUMMARY: The median onset of IGTN from initiation of IDV/RTV therapy was 18.4 weeks. Four patients previously received IDV, with one of these experiencing prior IGTN. All patients required surgical management of IGTN. All patients received virologic benefit from ongoing antiretroviral therapy, and the majority of patients elected to maintain IDV/RTV combination therapy. Two patients experienced recurrent IGTN while receiving ongoing IDV/RTV combination therapy. DISCUSSION: IGTN and paronychia have previously been reported with IDV and lamivudine. IGTN in patients with HIV infection is more likely to present acutely, involve more digits, and require surgical management IDV increases retinoic acid signaling and, based on elevated IDV concentrations from concomitant RTV therapy, the risk of IGTN may be increased in patients receiving IDV/RTV combination therapy. CONCLUSIONS: With the increasing popularity of IDV/RTV combination therapy, clinicians should be aware of the potential increase in frequency of dose-related toxicities including IGTN. Evaluation of hands and feet on physical examination should be recommended for all patients being treated with lamivudine and IDV, especially when used in combination with RTV.
Asunto(s)
Inhibidores de la Proteasa del VIH/efectos adversos , Indinavir/efectos adversos , Uñas Encarnadas/inducido químicamente , Ritonavir/efectos adversos , Adulto , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Uñas Encarnadas/cirugía , Estudios Prospectivos , RecurrenciaRESUMEN
The authors report an unusual case of multiple onychocryptosis, which developed following treatment of onychomycosis with oral terbinafine. With new growth of the healthy nail plate, the distal aspect of multiple toenails became ingrown with periungual inflammation. This required several minor surgical procedures to alleviate the onychocryptosis. The authors present this case report as a potential complication of oral antifungal therapy.
Asunto(s)
Antifúngicos/efectos adversos , Dermatosis del Pie/tratamiento farmacológico , Uñas Encarnadas/inducido químicamente , Naftalenos/efectos adversos , Onicomicosis/tratamiento farmacológico , Administración Oral , Antifúngicos/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Naftalenos/administración & dosificación , TerbinafinaAsunto(s)
Queilitis/inducido químicamente , Infecciones por VIH/tratamiento farmacológico , Indinavir/efectos adversos , Uñas Encarnadas/inducido químicamente , Paroniquia/inducido químicamente , Inhibidores de Proteasas/efectos adversos , Enfermedades de la Piel/inducido químicamente , Adolescente , Adulto , Queilitis/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
Many persons with haemophilia suffer from HIV and receive highly active antiretroviral therapy. Three patients received indinavir and required surgery due to ingrown toenails. Two patients suffered from a traumatic subungual haematoma. The treatment protocol is described whereby the pressure exerted onto the germinal layer and the nail bed is relieved in order to alleviate pain and nail matrix damage.
Asunto(s)
Hemofilia A/complicaciones , Enfermedades de la Uña/etiología , Uñas/patología , Trastornos Relacionados con Sustancias/complicaciones , Adulto , Granuloma Piogénico/inducido químicamente , Granuloma Piogénico/etiología , Granuloma Piogénico/patología , Inhibidores de la Proteasa del VIH/efectos adversos , Inhibidores de la Proteasa del VIH/uso terapéutico , Hematoma/inducido químicamente , Hematoma/etiología , Hematoma/patología , Hemofilia A/tratamiento farmacológico , Hemofilia A/virología , Hemofilia B/complicaciones , Hemofilia B/tratamiento farmacológico , Hemofilia B/virología , Humanos , Indinavir/efectos adversos , Indinavir/uso terapéutico , Persona de Mediana Edad , Enfermedades de la Uña/inducido químicamente , Enfermedades de la Uña/patología , Uñas/irrigación sanguínea , Uñas/lesiones , Uñas Encarnadas/inducido químicamente , Uñas Encarnadas/etiología , Uñas Encarnadas/patología , Trastornos Relacionados con Sustancias/patologíaRESUMEN
Lamivudine and indinavir are two medications used to treat human immunodeficiency virus (HIV) that have recently been reported to cause paronychia. The nails of the great toes are commonly affected. This is the second report of paronychia and ingrown toenails due to indinavir and the first report of recurrent paronychia and ingrown toenails associated with this drug.
Asunto(s)
Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/efectos adversos , VIH-1/aislamiento & purificación , Indinavir/efectos adversos , Uñas Encarnadas/inducido químicamente , Paroniquia/inducido químicamente , Adulto , Inhibidores de la Proteasa del VIH/uso terapéutico , Humanos , Indinavir/uso terapéutico , Masculino , Uñas Encarnadas/fisiopatología , Paroniquia/fisiopatología , Recurrencia , Dedos del PieAsunto(s)
Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Proteasa del VIH/efectos adversos , Indinavir/efectos adversos , Uñas Encarnadas/inducido químicamente , Adulto , Anciano , Fármacos Anti-VIH/uso terapéutico , Estudios de Casos y Controles , Quimioterapia Combinada , Femenino , Inhibidores de la Proteasa del VIH/uso terapéutico , Humanos , Indinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Inhibidores de la Transcriptasa Inversa/uso terapéuticoRESUMEN
With the advent of effective oral therapies for onychomycosis, there have been anecdotal reports of an increased incidence of onychocryptosis associated with the use of these new agents. The authors undertook a chart review of 100 consecutive patients treated for onychomycosis in a private medical practice to determine the incidence of onychocryptosis. A total of 37 of these patients (37%) developed paronychia ranging from simple pain to a severe inflammatory response with redness, drainage, and granuloma formation. Of these, 19 patients (19%) required surgical procedures to control onychocryptotic symptoms. Podiatric physicians should be aware that ingrown toenails may be an adverse consequence of effective treatment for onychomycosis.
Asunto(s)
Antifúngicos/efectos adversos , Uñas Encarnadas/inducido químicamente , Onicomicosis/tratamiento farmacológico , Administración Oral , Adulto , Antifúngicos/uso terapéutico , Femenino , Humanos , Persona de Mediana Edad , Uñas Encarnadas/complicacionesRESUMEN
AIDS: A French study confirms recent reports of hair loss in men as a side effect of the protease inhibitor Crixivan (Indinavir). All ten men in the study experienced various types of hair loss, which grew back several months after switching to another protease inhibitor or NNRTI. Ingrown toenails are another side effect recorded by a different French study, corroborating reports from patients taking Crixivan. Patients on Crixivan, experiencing these symptoms, should discuss them with their doctor.^ieng